{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.1","upperLimit":"20.5","value":"11.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both median point estimate and 90% confidence interval (CI) estimate.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From start of treatment to time of progression or death, whichever occurs first, assessed up to 60 months after the last dose of vorinostat maximum treatment duration= 24 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}